Postprandial elevation of tissue factor antigen in the blood of healthy adults

Summary

Atherosclerosis is a dynamic disease involving lipid metabolism, inflammation and thrombosis. A key factor in thrombosis is tissue factor, a small transmembrane glycoprotein. Tissue factor binds FactorVIIa, and this complex converts Factor X to Factor Xa, leading to thrombin generation and fibrin formation. Inhibition of this pathway is by tissue factor pathway inhibitor (TFPI). Tissue factor is found sequestered within atherosclerotic plaques, and plaque rupture allows tissue factor exposure to the circulation, leading to formation of a thrombus. Tissue factor is also associated with membrane microparticles in the circulation, most likely released from monocytes activated by an inflammatory event. We hypothesize that consumption of a typical western diet that is moderate in fat content leads to elevated levels of circulating tissue factor that may act as a marker of a pro-thrombotic state. Healthy volunteers, aged 18-55, consumed a moderate (40%) fat meal, with blood taken before and 3.5 and 6 h after the meal. Plasma was isolated and assayed for plasma triglycerides, tissue factor, thrombin antithrombin (TAT) complexes, TFPI and TNFα. The levels of circulating tissue factor increased 56% (from 78 pg/ml to120 pg/ml) 3.5 h after the meal. Levels decreased, but had not returned to baseline 6 h postprandially. No significant differences in TAT, TFPI and TNFá levels were observed postprandially. These results demonstrate increased tissue factor levels in individuals who consumed a moderate fat diet. This suggests that the typical western diet may play a larger role in cardiovascular disease than merely altering lipid profiles.

Keywords

Tissue factor - postprandial lipemia - diet - atherosclerosis

• References

• 1 Doshi SN, Marmur JD. Evolving role of tissue factor and its pathway inhibitor.. Crit Care Med 2002; 30 (Suppl. 05) S241-50.
• 2 Mackman N. Role of tissue factor in hemostasis, thrombosis, and vascular development.. Arterioscler Thromb Vasc Biol 2004; 24: 1015-22.
• 3 Bochkov VN, Mechtcheriakova D, Lucerna M. et al. Oxidized phospholipids stimulate tissue factor expression in human endothelial cells via activation of ERK/EGR-1 and Ca(++)/NFAT.. Blood 2002; 99: 199-206.
• 4 Drake TA, Hannani K, Fei HH. et al. Minimally oxidized low-density lipoprotein induces tissue factor expression in cultured human endothelial cells.. Am J Pathol 1991; 138: 601-7.
• 5 Bogdanov VY, Balasubramanian V, Hathcock J. et al. Alternatively spliced human tissue factor: a circulating, soluble, thrombogenic protein.. Nat Med 2003; 9: 458-62.
• 6 Biro E, Sturk-Maquelin KN, Vogel GM. et al. Human cell-derived microparticles promote thrombus formation in vivo in a tissue factor-dependent manner.. J Thromb Haemost 2003; 1: 2561-8
• 7 Mallat Z, Hugel B, Ohan J. et al. Shed membrane microparticles with procoagulant potential in human atherosclerotic plaques: a role for apoptosis in plaque thrombogenicity.. Circulation 1999; 99: 348-53.
• 8 Tremoli E, Camera M, Toschi V. et al. Tissue factor in atherosclerosis.. Atherosclerosis 1999; 144: 273-83.
• 9 Wilcox JN, Smith KM, Schwartz SM. et al. Localization of tissue factor in the normal vessel wall and in the atherosclerotic plaque.. Proc Natl Acad Sci U S A 1989; 86: 2839-43.
• 10 Mallat Z, Benamer H, Hugel B. et al. Elevated levels of shed membrane microparticles with procoagulant potential in the peripheral circulating blood of patients with acute coronary syndromes.. Circulation 2000; 101: 841-3.
• 11 Misumi K, Ogawa H, Yasue H. et al. Comparison of plasma tissue factor levels in unstable and stable angina pectoris.. Am J Cardiol 1998; 81: 22-6.
• 12 Ohkura N, Hiraishi S, Itabe H. et al. Oxidized phospholipids in oxidized low-density lipoprotein re-duce the activity of tissue factor pathway inhibitor through association with its carboxy-terminal region.. Antioxid Redox Signal. 2004; 6: 705-12.
• 13 Crawley J, Lupu F, Westmuckett AD. et al. Expression, localization, and activity of tissue factor pathway inhibitor in normal and atherosclerotic human vessels.. Arterioscler Thromb Vasc Biol 2000; 20: 1362-73.
• 14 Hyson D, Rutledge JC, Berglund L. Postprandial lipemia and cardiovascular disease.. Curr Atheroscler Rep 2003; 5: 437-44.
• 15 Boccalandro F, Farias J, Boccalandro C. et al. Frequency of postprandial lipemia after a first acute coronary event (unstable angina pectoris or non-ST-segment elevation acute myocardial infarction) and the effects of atenolol on the lipemia.. Am J Cardiol 2002; 90: 153-6.
• 16 Karpe F. Postprandial lipoprotein metabolism and atherosclerosis.. J Intern Med 1999; 246: 341-55.
• 17 Hyson DA, Paglieroni TG, Wun T. et al. Postprandial lipemia is associated with platelet and monocyte activation and increased monocyte cytokine expression in normolipemic men.. Clin Appl Thromb Hemost 2002; 8: 147-55.
• 18 Nappo F, Esposito K, Cioffi M. et al. Postprandial endothelial activation in healthy subjects and in type 2 diabetic patients: role of fat and carbohydrate meals.. J Am Coll Cardiol 2002; 39: 1145-50.
• 19 vanOostrom AJ, Sijmonsma TP, Verseyden C. et al. Postprandial recruitment of neutrophils may contribute to endothelial dysfunction.. J Lipid Res 2003; 44: 576-83.
• 20 Laird NM, Ware JH. Random-effects models for longitudinal data.. Biometrics 1982; 38: 963-74.
• 21 Muller I, Klocke A, Alex M. et al. Intravascular tissue factor initiates coagulation via circulating microvesicles and platelets.. Faseb J 2003; 17: 476-8.
• 22 Siddiqui FA, Desai H, Amirkhosravi A. et al. The presence and release of tissue factor from human platelets.. Platelets 2002; 13: 247-53.
• 23 Del Conde I, Shrimpton CN, Thiagarajan P. et al. Tissue factor-bearing microvesicles arise from lipid rafts and fuse with activated platelets to initiate coagulation.. Blood. 2005 (E-pub).
• 24 Annex BH, Denning SM, Channon KM. et al. Differential expression of tissue factor protein in directional atherectomy specimens from patients with stable and unstable coronary syndromes.. Circulation 1995; 91: 619-22.
• 25 Amengual O, Atsumi T, Khamashta MA. et al. The role of the tissue factor pathway in the hypercoagulable state in patients with the antiphospholipid syndrome.. Thromb Haemost 1998; 79: 276-81.
• 26 Key NS, Slungaard A, Dandelet L. et al. Whole blood tissue factor procoagulant activity is elevated in patients with sickle cell disease.. Blood 1998; 91: 4216-23.
• 27 Nieuwland R, Berckmans RJ, McGregor S. et al. Cellular origin and procoagulant properties of microparticles in meningococcal sepsis.. Blood 2000; 95: 930-5.
• 28 Wada H, Kaneko T, Wakita Y. et al. Effect of lipoproteins on tissue factor activity and PAI-II antigen in human monocytes and macrophages.. Int J Cardiol 1994; 47 (Suppl. 01) S21-5.
• 29 Pelzer H, Schwarz A, Heimburger N. Determination of human thrombin-antithrombin III complex in plasma with an enzyme-linked immunosorbent assay.. Thromb Haemost 1988; 59(1): 101-6.
• 30 Karas RH. Current controversies regarding the cardiovascular effects of hormone therapy.. Clin Obstet Gynecol 2004; 47: 489-99.
• 31 Kujovich JL. Hormones and pregnancy: thromboembolic risks for women.. Br J Haematol 2004; 26: 443-54.
• 32 Quehenberger P, Kapiotis S, Partan C. et al. Studies on oral contraceptive-induced changes in blood coagulation and fibrinolysis and the estrogen effect on endothelial cells.. Ann Hematol 1993; 67: 33-6.
• 33 Bajaj MS, Birktoft JJ, Steer SA. et al. Structure and biology of tissue factor pathway inhibitor.. Thromb Haemost. 2001; 86: 959-72.
• 34 Caplice NM, Panetta C, Peterson TE. et al. Lipoprotein (a) binds and inactivates tissue factor pathway inhibitor: a novel link between lipoproteins and thrombosis.. Blood. 2001; 98: 2980-7.